118 related articles for article (PubMed ID: 8494999)
1. Myelodysplastic syndromes: from morphology to molecular biology. Part II. The molecular genetics of myelodysplasia.
Stephenson J; Mufti GJ; Yoshida Y
Int J Hematol; 1993 Apr; 57(2):99-112. PubMed ID: 8494999
[TBL] [Abstract][Full Text] [Related]
2. Molecular genetic aspects of myelodysplastic syndromes.
Bartram CR
Hematol Oncol Clin North Am; 1992 Jun; 6(3):557-70. PubMed ID: 1613006
[TBL] [Abstract][Full Text] [Related]
3. A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome.
Hirai H; Kobayashi Y; Mano H; Hagiwara K; Maru Y; Omine M; Mizoguchi H; Nishida J; Takaku F
Nature; 1987 Jun 4-10; 327(6121):430-2. PubMed ID: 3295562
[TBL] [Abstract][Full Text] [Related]
4. [Molecular abnormalities and clonality in myelodysplastic syndromes].
Fenaux P; Preudhomme C
Pathol Biol (Paris); 1997 Sep; 45(7):556-60. PubMed ID: 9404479
[TBL] [Abstract][Full Text] [Related]
5. NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
Fidler C; Watkins F; Bowen DT; Littlewood TJ; Wainscoat JS; Boultwood J
Haematologica; 2004 Jul; 89(7):865-6. PubMed ID: 15257941
[TBL] [Abstract][Full Text] [Related]
6. [N-ras and fms gene mutation in idiopathic thrombocytopenic purpura and myelodysplasia].
Zhao HY; Hou M; Li XF; Ma DX; Liu QJ; Wang P
Zhonghua Xue Ye Xue Za Zhi; 2008 Mar; 29(3):158-60. PubMed ID: 18788612
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
8. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.
Eisenmann KM; Dykema KJ; Matheson SF; Kent NF; DeWard AD; West RA; Tibes R; Furge KA; Alberts AS
Oncogene; 2009 Oct; 28(39):3429-41. PubMed ID: 19597464
[TBL] [Abstract][Full Text] [Related]
9. Genetic lesions in preleukemia.
Carter G; Ridge S; Padua RA
Crit Rev Oncog; 1992; 3(4):339-64. PubMed ID: 1420444
[TBL] [Abstract][Full Text] [Related]
10. The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia.
Cermák J; Belicková M; Krejcová H; Michalová K; Zilovcová S; Zemanová Z; Brezinová J; Sieglová Z
Leuk Res; 2005 Apr; 29(4):371-9. PubMed ID: 15725470
[TBL] [Abstract][Full Text] [Related]
11. Leukemic transformation in myelodysplastic syndrome: a review.
Yanuck MD; Saleem A
Ann Clin Lab Sci; 1991; 21(3):171-6. PubMed ID: 2064303
[TBL] [Abstract][Full Text] [Related]
12. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
13. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia.
Omidvar N; Kogan S; Beurlet S; le Pogam C; Janin A; West R; Noguera ME; Reboul M; Soulie A; Leboeuf C; Setterblad N; Felsher D; Lagasse E; Mohamedali A; Thomas NS; Fenaux P; Fontenay M; Pla M; Mufti GJ; Weissman I; Chomienne C; Padua RA
Cancer Res; 2007 Dec; 67(24):11657-67. PubMed ID: 18089795
[TBL] [Abstract][Full Text] [Related]
14. Molecular bases of myelodysplastic syndromes: lessons from animal models.
Komeno Y; Kitaura J; Kitamura T
J Cell Physiol; 2009 Jun; 219(3):529-34. PubMed ID: 19259975
[TBL] [Abstract][Full Text] [Related]
15. Mutations in ras genes in myelocytic leukemias and myelodysplastic syndromes.
Bartram CR
Blood Cells; 1988; 14(2-3):533-8. PubMed ID: 3067784
[TBL] [Abstract][Full Text] [Related]
16. Novel variant isoform of G-CSF receptor involved in induction of proliferation of FDCP-2 cells: relevance to the pathogenesis of myelodysplastic syndrome.
Awaya N; Uchida H; Miyakawa Y; Kinjo K; Matsushita H; Nakajima H; Ikeda Y; Kizaki M
J Cell Physiol; 2002 Jun; 191(3):327-35. PubMed ID: 12012328
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia.
Shih LY; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Kuo MC; Tang TC
Clin Cancer Res; 2005 Mar; 11(5):1821-6. PubMed ID: 15756005
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.
Bernasconi P
Br J Haematol; 2008 Sep; 142(5):695-708. PubMed ID: 18540941
[TBL] [Abstract][Full Text] [Related]
19. Absence of p16 and p27 gene rearrangements and mutations in de novo myelodysplastic syndromes.
Papageorgiou SG; Pappa V; Papageorgiou E; Tsirigotis P; Kontsioti F; Panani A; Dervenoulas J; Economopoulos T
Eur J Haematol; 2005 Sep; 75(3):193-8. PubMed ID: 16104874
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic aspects of adult primary myelodysplastic syndromes: clinical implications.
Panani AD; Roussos C
Cancer Lett; 2006 Apr; 235(2):177-90. PubMed ID: 15935553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
